MYC

  • Headshot of Bill Tansey overlaid over a gold background with the Vanderbilt V on the left and

    Promising drug-like compounds found to have strong action against blood cancers

    For researchers, projects can sometimes feel like babies, and there is nothing more satisfying than seeing your baby grow up. For William Tansey, professor of cell and developmental biology, this baby started 10 years ago when he and Stephen Fesik, Orrin H. Ingram II, Professor of Cancer Research and professor of biochemistry, discovered that a protein called WDR5 is a “partner in crime” to MYC, a transcription factor and oncogene that is often mutated in cancers. In fact, dysregulation of MYC is estimated to be responsible for about a third of all cancer deaths annually. Read More

    Sep. 3, 2024

  • Vanderbilt University

    New cancer target could push new drugs into the clinic

    New work by Professor of Cell and Developmental Biology Bill Tansey and colleagues has determined that a new type of inhibitor—a WINi—targets cancer cells in a novel way and suggests exploiting this pathway in future anticancer drug development efforts. Read More

    May. 14, 2024